ArticlePatient education and counseling2025
Communicating therapeutic indication information in direct-to-consumer television ads for prescription cancer drugs: Exploring the effect of dual-modality presentations.
Article in Patient education and counseling, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
objectiveThe rise in direct-to-consumer (DTC) ads for cancer drugs, which often have complex indications, raises concerns about consumer misunderstanding. A drug's indication must clearly convey its condition(s) of use, which may include elements such as the approved patient population, second-line treatment status, and whether it is adjunctive or concomitant therapy. The study examines whether the modality used to communicate the drug's indication in DTC television ads affects consumers' recognition, recall, and comprehension.
methodsWe conducted two experimental studies testing dual-modality (voiceover and on-screen text) presentations of therapeutic indication information in television ads for non-small cell lung cancer (N = 281) and multiple myeloma (N = 287). In each study, the indication statement for all ads presented the medical condition in dual modality and varied the modality used to present additional elements of the indication (absent, audio-only, text-only, dual-modality). After viewing the ad twice, participants completed a questionnaire that measured indication recognition, recall, and comprehension.
resultsDual-modality presentations led to improved communication outcomes relative to the control condition without unintended detrimental effects relative to single-modality presentations. Participants exposed to dual-modality presentations were more likely to correctly recognize the full indication statement and the drug's intended use. The dual-modality presentation also improved recall and comprehension of the indication's additional elements in one study, though not consistently across both. No consistent pattern emerged linking specific single modalities to better outcomes. In line with previous research, our results present nuanced outcomes, revealing the superior benefits of dual-modality presentations for some outcomes, but highlighting the influence of moderating factors.
conclusionsDual-modality presentations of indication statements may improve individuals' recall, recognition, and comprehension of indication statements and facilitate better consumer understanding. PRACTICE IMPLICATIONS: These results support stakeholders continuing to investigate how indication statement complexity affects consumer understanding and expectations about drug eligibility.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.